HLS
$229M—
Healius
Medical imaging
One of Australia's largest pathology and imaging networks
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.0M
Dec 2025 4C
Runway
—Based on Dec 2025 4C
Market Cap
$229M
Burn Rate
$1.0M/qtr
Dec 2025 4C
Shares Outstanding
726M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther12 May 2026
FY26 trading update and strategic review of assets
Healius updated FY26 guidance with EBITDA of $259-264m and EBIT of $30-35m. The company announced a strategic review and potential sale of subsidiary Agilex Biolabs (growing 13.7% YTD) via UBS Securities following unsolicited approaches. Fair Work Commission gender undervaluation decision will impact pathology labour costs by $1.8m in Q4 2026, with ongoing pressures from frozen Medicare indexation.
3M Price
HLS.ASX$0.315-47.1% 3M
Low $0.315High $0.595
Pipeline Assets (2)
Montserrat Day HospitalsDay hospital / procedural services
ApprovedLumus ImagingDiagnostic radiology and imaging
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
4 transactionsLast 90dNo Activity
Buys0-3 vs prior
Sells0
warning2 directors bought within 30 days (03-12 – 03-12) — $87k total
PERFORMANCE RIGHTSKatherine Ostinopen_in_new
Catalysts (4)
Expectedarrow_upwardHigh31 Aug 2026(2× delayed)
Expectedarrow_upwardHigh31 Dec 2026
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
What drove these scores · rolling 2yr
arrow_drop_down
FY2026 EBIT target test (~$48M) — Upcoming — delayed 2× from original date
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Announcements(20)
article
substantial_holderauto_awesome
Ceasing to be a substantial holder from MQG29 May 2026
expand_more160KB
article
substantial_holderauto_awesome
Becoming a substantial holder from MQG26 May 2026
expand_more203KB
article
substantial_holderauto_awesome
Ceasing to be a substantial holder from MQG22 May 2026
expand_more154KB